Search

Your search keyword '"Preudhomme, Claude"' showing total 1,760 results

Search Constraints

Start Over You searched for: Author "Preudhomme, Claude" Remove constraint Author: "Preudhomme, Claude"
1,760 results on '"Preudhomme, Claude"'

Search Results

3. Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens

4. Prognostic impact of CEBPA mutational subgroups in adult AML

5. Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial

6. Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL

7. Prognostic impact of RUNX1 mutations and deletions in pediatric acute myeloid leukemia: results from the French ELAM02 study group

8. Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression

10. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41

11. LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study

12. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia

13. Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group

14. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study

15. Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML

16. Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

19. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

20. Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML

21. Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML

23. A multiparametric niche-like drug screening platform in acute myeloid leukemia

24. Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis

25. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia

26. Prognostic impact of CEBPA mutational subgroups in adult AML

27. A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis

28. Monitoring molecular changes in the management of myelodysplastic syndromes.

30. Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease

32. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results

33. Clonal Dynamics of FLT3-ITD Positive Acute Myeloid Leukemia Patients with Relapsed/Refractory Disease Following Intensive Chemotherapy +/- Midostaurin

34. Impact of Residence in an Agricultural Zone on AML Characteristics

35. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

36. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?

38. Familial myeloid malignancies with germline TET2 mutation

39. Small myeloid subclones are present at diagnosis of multiple myeloma in patients who develop secondary myelodysplastic syndromes

40. Tetraspanin CD81 promotes leukemia stem cell function and represents a new therapeutic vulnerability in acute myeloid leukemia

41. Three UBA1 clones for a unique VEXAS syndrome

43. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

44. Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia

45. The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia

46. Clinical impact of genetic alterations including germline DDX41mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens

47. TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML

49. The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants

50. Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia

Catalog

Books, media, physical & digital resources